Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using finasteride, minoxidil, and a dermaroller for 80 days to treat hair loss. Early results are noted, but significant improvement is expected in 3–6 months.

HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.

The user "StrummerBummer" has been taking finasteride for 25 years without side effects, but is now switching to dutasteride. Other users congratulate and support the decision.

Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.

A 28-year-old is assessing their hair loss on the Norwood scale, considering adding topical minoxidil and dermastamping to their current regimen of oral finasteride and minoxidil. They feel their hair loss is worsening and seek opinions on their condition.

A man in his 40s treating his slow balding with a daily regimen of 2.5% spironolactone topical solution and Piroctone Olamine Shampoo. Despite initial hair shedding, he experienced no side effects and plans to continue the treatment for at least a year.

The user shared impressive hair growth results after 100 days using finasteride, minoxidil, biotin, and saw palmetto, and plans to get a hair transplant. The conversation includes suggestions for additional treatments like ketoconazole and derma stamping, and discussions about potential side effects of finasteride.

A user experienced facial swelling while taking spironolactone for androgenic alopecia, despite its diuretic properties. They are unsure about increasing the dose due to this side effect.

The user has been using oral finasteride for 15 years and is considering switching to a finasteride/minoxidil spray due to concerns about potential side effects like depression. They are seeking advice on whether to continue with both treatments or switch exclusively to the spray.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

KX-826 may cause increased hair loss for some users, leading to concerns about its effects. One user reported no issues but also no hair regrowth, only maintenance.

A 19-year-old has completed 70 days using oral and topical Minoxidil, oral finasteride, a dermaroller, and ketoconazole for hair regrowth. They are seeking feedback on the effectiveness of their treatment.

The conversation discusses hair regrowth after 100 days using 5mg Minoxidil and 0.5mg Dutasteride, focusing on changes in the temples and hairline. Users debate the effectiveness due to inconsistent photo comparisons.

The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.

The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.

The conversation discusses Dr. Blake Bloxham's experiment with Verteporfin for hair loss, with one person suggesting more doctors should try it as it seems beneficial. Another comment notes that results at 4-5 months were not very impressive.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

Hair loss treatments, specifically Spironolactone, and the user's experience with it over a 7-8 month period. Other treatments mentioned include Minoxidil and Finasteride.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

A transgender individual began MTF HRT with estradiol and spironolactone at 39 and is monitoring hair regrowth before starting minoxidil. They are hopeful about not needing wigs permanently.